leflunomide ch leflunomide 10mg tablet bottle
southern cross pharma pty ltd - leflunomide, quantity: 10 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; colloidal anhydrous silica; povidone; crospovidone; magnesium stearate; lactose monohydrate; maize starch; titanium dioxide; hypromellose; macrogol 4000 - treatment of active rheumatoid arthritis. the combined use of leflunomide with other disease modifying antirheumatic drugs (dmards) has not been adequately studied (see precautions).
leflunomide ch leflunomide 20mg tablet bottle
southern cross pharma pty ltd - leflunomide, quantity: 20 mg - tablet, film coated - excipient ingredients: magnesium stearate; crospovidone; maize starch; povidone; colloidal anhydrous silica; lactose monohydrate; microcrystalline cellulose; titanium dioxide; hypromellose; purified talc; iron oxide yellow; macrogol 6000 - treatment of active rheumatoid arthritis. the combined use of leflunomide with other disease modifying antirheumatic drugs (dmards) has not been adequately studied (see precautions).
leflunomide sz leflunomide 100mg tablet blister pack
southern cross pharma pty ltd - leflunomide, quantity: 100 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; povidone; colloidal anhydrous silica; crospovidone; maize starch; lactose monohydrate; magnesium stearate; titanium dioxide; hypromellose; macrogol 4000 - treatment of active rheumatoid arthritis. the combined use of leflunomide with other disease modifying antirheumatic drugs (dmards) has not been adequately studied (see precautions).
leflunomide tablet
kvk-tech, inc. - leflunomide (unii: g162gk9u4w) (leflunomide - unii:g162gk9u4w) - leflunomide tablets are indicated for the treatment of adults with active rheumatoid arthritis (ra). leflunomide tablets are contraindicated in: - pregnant women. leflunomide tablets may cause fetal harm. if a woman becomes pregnant while taking this drug, stop leflunomide tablets, apprise the patient of the potential hazard to the fetus, and begin a drug elimination procedure [see warnings and precautions (5.1 and 5.3) and use in specific populations (8.1 )]. patients with severe hepatic impairment [see warnings and precautions (5.2) ]. - patients with known hypersensitivity to leflunomide or any of the other components of leflunomide tablets. known reactions include anaphylaxis [see adverse reactions (6.1) ]. - patients being treated with teriflunomide [see drug interactions (7) ]. risk summary leflunomide tablets are contraindicated for use in pregnant women because of the potential for fetal harm. in animal reproduction studies, oral administration of leflunomide during organogenesis at a dose of 1/10 of
leflunomide tablet, film coated
lupin pharmaceuticals, inc. - leflunomide (unii: g162gk9u4w) (leflunomide - unii:g162gk9u4w) - leflunomide tablets usp are indicated for the treatment of adults with active rheumatoid arthritis (ra). leflunomide tablet is contraindicated in: - pregnant women. leflunomide tablets may cause fetal harm. if a woman becomes pregnant while taking this drug, stop leflunomide tablets, apprise the patient of the potential hazard to the fetus, and begin a drug elimination procedure [see warnings and precautions (5.1 and 5.3) and use in specific populations (8.1)]. - patients with severe hepatic impairment [see warnings and precautions (5.2)]. - patients with known hypersensitivity to leflunomide or any of the other components of leflunomide tablets. known reactions include anaphylaxis [see adverse reactions (6.1)]. - patients being treated with teriflunomide [see drug interactions (7)]. risk summary leflunomide tablet is contraindicated for use in pregnant women because of the potential for fetal harm. in animal reproduction studies, oral administration of leflunomi
leflunomide tablet, film coated
aurobindo pharma limited - leflunomide (unii: g162gk9u4w) (leflunomide - unii:g162gk9u4w) - leflunomide tablets are indicated for the treatment of adults with active rheumatoid arthritis (ra). leflunomide tablets are contraindicated in: - pregnant women. leflunomide tablets may cause fetal harm. if a woman becomes pregnant while taking this drug, stop leflunomide tablets, apprise the patient of the potential hazard to the fetus, and begin a drug elimination procedure [see warnings and precautions (5.1 and 5.3) and use in specific populations (8.1)]. - patients with severe hepatic impairment [see warnings and precautions (5.2)]. - patients with known hypersensitivity to leflunomide or any of the other components of leflunomide tablets. known reactions include anaphylaxis [see adverse reactions (6.1)]. - patients being treated with teriflunomide [see drug interactions (7)]. pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to leflunomide during pregnancy. health care providers and patients are encouraged to report pregnancies by calli
leflunomide 20mg film-coated tablets
aspire pharma limited - leflunomide - film-coated tablet - 20 milligram(s) - selective immunosuppressants; leflunomide
leflunomide 10 mg film-coated tablets
aspire pharma limited - leflunomide - film-coated tablet - 10 milligram(s) - selective immunosuppressants; leflunomide
leflunomide 10 mg film-coated tablets
european regulatory affairs t/a ivowen - leflunomide - film-coated tablet - 10 milligram(s) - selective immunosuppressants; leflunomide
leflunomide 20mg film-coated tablets
european regulatory affairs t/a ivowen - leflunomide - film-coated tablet - 20 milligram(s) - selective immunosuppressants; leflunomide